David Simpson
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 45
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 36
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 15
- Multiple Myeloma Research and Treatments 8
- Oncology top 5%
- Cancer Treatment and Pharmacology 7
- Viral-associated cancers and disorders 6
- Immunology top 10%
-
- Lung Cancer Treatments and Mutations 6
-
- Acute Lymphoblastic Leukemia research 6
- Co-authors
- Samar IssaPeter WoodDavid MacDonaldIan W. FlinnJohn M. BurkeKathryn S. KolibabaTim E. HawkinsBrad S. Kahl
- Partner nations
- New ZealandUnited StatesAustralia
In The Last Decade
David Simpson
76 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Genetics 1.1k
- Pathology and Forensic Medicine 1.3k
- Hematology 438
- Oncology 830
- Immunology 329
Countries citing papers authored by David Simpson
This map shows the geographic impact of David Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Simpson more than expected).
Fields of papers citing papers by David Simpson
This network shows the impact of papers produced by David Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Simpson. The network helps show where David Simpson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Simpson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 32 | |
| 2 | 2021 | 63 | |
| 3 | 2021 | 1 | |
| 4 | 2020 | 73 | |
| 5 | 2019 | 3 | |
| 6 | 2019 | 15 | |
| 7 | 2019 | 57 | |
| 8 | 2017 | 10 | |
| 9 | 2017 | 29 | |
| 10 | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studybreakdown → | 2014 | 419 |
| 11 | 2009 | 72 | |
| 12 | 2004 | 46 | |
| 13 | 2002 | 9 | |
| 14 | 2002 | 49 | |
| 15 | 2002 | 12 | |
| 16 | 2001 | 18 | |
| 17 | 2001 | 3 | |
| 18 | 2000 | 17 | |
| 19 | 1999 | 16 | |
| 20 | 1993 | 13 |
About David Simpson
David Simpson is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Neurology, having authored 77 papers that have together received 2.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (36 papers), Chronic Myeloid Leukemia Treatments (15 papers), Multiple Myeloma Research and Treatments (8 papers), Cancer Treatment and Pharmacology (7 papers), Viral-associated cancers and disorders (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Acute Lymphoblastic Leukemia research (6 papers). The work is most often cited by research in Genetics (1.1k citations), Pathology and Forensic Medicine (1.3k citations), Hematology (438 citations), Oncology (830 citations) and Immunology (329 citations). David Simpson has collaborated with scholars based in New Zealand, United States and Australia. Frequent co-authors include Samar Issa, Peter Wood, David MacDonald, Ian W. Flinn, John M. Burke, Kathryn S. Kolibaba, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, HemaSphere and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.